Skip to main content

Table 2 Treatment of each respiratory symptoms group

From: Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study

 

All (n = 3314)

Group 1 (n = 605)

Group 2 (n = 331)

Group 3 (n = 1229)

Group 4 (n = 1149)

p value

Remdesivir, %

35.8

24

16.4

46.9

35.9

 < 0.0001a = **/b = **/c = **

Antibiotics, %

23.2

20.3

12.7

30.6

20.1

 < 0.0001a = **/b = **

Steroids, %

50.4

38.1

24.6

64.7

49.2

 < 0.0001a = **/b = **/c = **

Tocilizumab, %

9.8

5

3.3

15.2

8.5

 < 0.0001b = **/c = **

Baricitinib, %

5.2

31.4

14.3

53.6

42.9

0.0014b = *

Anti-coagulant drugs, %

29.3

21

14

41.3

25.4

 < 0.0001a = **/b = **/c = *

  1. Data are shown as mean ± standard deviation
  2. aComparison of patients in group 1 versus group 2
  3. bComparison of patients in group 1 versus group 3
  4. cComparison of patients in group 1 versus group 4
  5. *p < 0.05 **p < 0.01